The glucose is metabolised by the microbes in the jejunum and ileum. Ogawa thinks the glucose is feeding the gut microbes, which, in turn, promotes the production of SCFAs.

Pharmacokinetics: PK analysis confirmed the delayed-release, terminal ileum-targeted and colon-targeted profile of PALI-2108.